GENEiQ
- Company typePrivate
- Founded2017
- HeadquartersDallas, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
GENEiQ firmographics
Firmographics- Name
- GENEiQ
- Website
- https://geneiqlab.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Unknown
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
GENEiQ industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Medical and Diagnostic Laboratories (6215)
- SIC
- Services-Medical Laboratories (8071), Services-Testing Laboratories (8734)
- akta.pro primary industry
- Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)
- akta.pro secondary industries
- Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD), Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA)
Keywords
Where GENEiQ is headquartered
LocationHeadquarters
- HQ city
- Dallas
- HQ country
- United States
- HQ region
- North America
Markets served
GENEiQ business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
GENEiQ product offering
Product offeringCore offering
GENEiQ is a biotechnology company that provides a multi-faceted PCR testing portfolio targeting urinary and respiratory pathogens. The company's core offering is molecular diagnostic testing services, leveraging nucleic acid amplification to detect infectious agents in clinical samples. Specific product or service details could not be verified as the company website (geneiqlab.com) is parked with GoDaddy and contains no active content.
Differentiator
Problem solved
Functional benefit
Products and services
- PCR Testing Portfolio for Urinary Pathogens
Companies that use GENEiQ
Customer profileIdeal customer profiles1 record
GENEiQ technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
GENEiQ competitors and assessment
Company assessmentDirect peers
- Cepheid (Danaher): Cepheid is the dominant provider of PCR-based molecular diagnostic tests for infectious diseases, including the widely used GeneXpert system with respiratory and urinary pathogen panels. It directly competes with GENEiQ in the same PCR pathogen testing categories.
- BioFire Diagnostics (bioMérieux): BioFire produces the FilmArray syndromic PCR panels for respiratory pathogens and bloodstream infections, and is the closest comparable to GENEiQ's multi-pathogen PCR testing approach for clinical use.
- Hologic (Panther Fusion / Diagnostics): Hologic's Panther Fusion system offers PCR-based respiratory and sexually transmitted infection testing, placing it as a direct competitor in the molecular diagnostics clinical testing market.
- Roche Molecular Diagnostics (cobas / GenMark ePlex): Roche, through cobas and the acquired GenMark ePlex syndromic panels, provides PCR-based respiratory and infectious disease testing that directly competes with GENEiQ's PCR pathogen portfolio.
- QIAGEN (NeuMoDx, QIAstat-Dx): QIAGEN develops QIAstat-Dx and NeuMoDx molecular PCR testing systems used for respiratory and other infectious disease diagnostics, making it a direct competitor in PCR pathogen testing.
- Meridian Bioscience: Meridian develops and commercializes molecular diagnostic tests, including PCR-based assays for infectious disease pathogens, serving a comparable clinical lab and hospital customer base.
Broad incumbents
- Quest Diagnostics: Quest is a large commercial clinical laboratory offering a broad menu of molecular, including PCR-based, infectious disease testing. It competes with GENEiQ for the same hospital and physician send-out volume, though across many test categories.
- Labcorp (Laboratory Corporation of America): Labcorp operates a national clinical lab network with PCR-based infectious disease testing in respiratory and urinary indications. It is a broader incumbent whose offerings overlap with GENEiQ's narrower PCR pathogen focus.
- Becton, Dickinson and Company (BD) — BD MAX System: BD's BD MAX System provides PCR-based molecular testing for respiratory, enteric, and sexually transmitted infections, making it an overlapping competitor in clinical infectious disease PCR testing with a broader product portfolio.
Emerging players
- T2 Biosystems: T2 Biosystems develops molecular diagnostic tests for infectious disease pathogens. While its core focus has been sepsis and bloodstream infections, it operates in the same molecular clinical diagnostics space as GENEiQ.
Market position
Customer concentration
GENEiQ social profiles
Digital presenceGENEiQ financial estimates
Financial estimateRevenue estimate
Valuation estimate
GENEiQ leadership team
Management profileNumber of profiles
Profiles2 records
GENEiQ funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GENEiQ M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GENEiQ
What does GENEiQ do?
GENEiQ is a biotechnology company that provides a multi-faceted PCR testing portfolio targeting urinary and respiratory pathogens. The company's core offering is molecular diagnostic testing services, leveraging nucleic acid amplification to detect infectious agents in clinical samples. Specific product or service details could not be verified as the company website (geneiqlab.com) is parked with GoDaddy and contains no active content.
When was GENEiQ founded?
GENEiQ was founded in 2017. It employs 51 to 100 people.
Where is GENEiQ based?
GENEiQ is headquartered in Dallas, United States, in the North America region.
Who are GENEiQ's main competitors?
Direct peers on record are Cepheid (Danaher), BioFire Diagnostics (bioMérieux), Hologic (Panther Fusion / Diagnostics), Roche Molecular Diagnostics (cobas / GenMark ePlex), QIAGEN (NeuMoDx, QIAstat-Dx) and Meridian Bioscience. Broad incumbents are Quest Diagnostics, Labcorp (Laboratory Corporation of America) and Becton, Dickinson and Company (BD) — BD MAX System. T2 Biosystems is listed as an emerging player.
Does GENEiQ have an API?
No public API is recorded for GENEiQ.
What industry is GENEiQ in?
GENEiQ's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAGADAF, Molecular & Genetic Testing (PCR/NGS/qPCR), with a secondary code of HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD). Its NAICS code is 621511 and its SIC code is 8071.